INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2016. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $183,000 | +76.0% | 1,446 | +16.2% | 0.00% | +100.0% |
| Q2 2018 | $104,000 | +35.1% | 1,244 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $77,000 | +2.7% | 1,244 | -3.1% | 0.00% | 0.0% |
| Q4 2017 | $75,000 | -8.5% | 1,284 | -9.4% | 0.00% | 0.0% |
| Q3 2017 | $82,000 | -44.2% | 1,417 | +16.5% | 0.00% | -50.0% |
| Q2 2017 | $147,000 | -2.0% | 1,216 | -8.1% | 0.00% | -33.3% |
| Q1 2017 | $150,000 | -3.8% | 1,323 | -8.1% | 0.00% | 0.0% |
| Q4 2016 | $156,000 | -75.0% | 1,439 | -62.1% | 0.00% | -72.7% |
| Q3 2016 | $625,000 | +15.3% | 3,800 | 0.0% | 0.01% | +10.0% |
| Q2 2016 | $542,000 | +11.1% | 3,800 | 0.0% | 0.01% | +11.1% |
| Q1 2016 | $488,000 | -14.1% | 3,800 | 0.0% | 0.01% | -10.0% |
| Q4 2015 | $568,000 | +2.0% | 3,800 | +13.1% | 0.01% | +11.1% |
| Q3 2015 | $557,000 | -65.1% | 3,360 | -49.1% | 0.01% | -18.2% |
| Q2 2015 | $1,594,000 | – | 6,600 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chicago Capital Management, LLC | 185,781 | $4,611,565 | 12.16% |
| Samsara BioCapital, LLC | 640,688 | $11,878,356 | 3.64% |
| ALPINE ASSOCIATES MANAGEMENT INC. | 2,203,295 | $40,849,089 | 2.14% |
| Versor Investments LP | 378,480 | $7,017,019 | 1.42% |
| Magnetar Financial LLC | 2,407,209 | $44,629,655 | 1.14% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,077,893 | $38,524,136 | 0.85% |
| Fort Baker Capital Management LP | 430,600 | $7,983,324 | 0.74% |
| EHP Funds Inc. | 84,210 | $1,561,253 | 0.73% |
| Terrapin Asset Management, LLC | 30,000 | $556,200 | 0.63% |
| AQR Arbitrage LLC | 734,970 | $13,626,344 | 0.61% |